Supriya Lifescience
Supriya Lifescience Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Supriya Lifescience Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Supriya Lifescience Ltd trades at a P/E of 37.66× and P/B of 6.57×.
Valuation
Profitability
Growth
Financial Health
Supriya Lifescience Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Supriya Lifescience Ltd, switchable between annual and quarterly views, consolidated or standalone.
Supriya Lifescience Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹7,839.02 Cr and reported EPS of ₹25.95.
Supriya Lifescience segment analysis: revenue and profit mix.
Disclosed business segments at Supriya Lifescience with their share of revenue and profit, switchable between consolidated and standalone reporting.
Supriya Lifescience discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Supriya Lifescience Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Supriya Lifescience Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Supriya Lifescience Ltd's investment case rests on 8 positive markers and 9 flagged concerns drawn from the latest reported filings.
What you're getting.
Robust profitability with 36.70% OPM, 20.80% ROE, and 27.50% ROCE.
Very low debt-to-equity ratio (0.01) indicates strong financial health.
High 68.3% promoter holding reflects strong insider confidence and stable management.
Strong 5-year EPS CAGR of 20.69% and revenue growth of 17.45%.
Impressive 5-year book value growth of 66.50% and CAPEX CAGR 45.94%.
What can break it.
Elevated P/E ratio (35.53) compared to sector suggests potential overvaluation.
Recent quarterly sales declined 9.69%, net profit fell 22.10%, raising concerns.
High stock volatility (Beta 1.99) and wide 52-week price range.
Relatively small market capitalization (₹6012 crore) increases stock price susceptibility.
Low dividend yield (0.10%) may not attract income-focused investors.
What would change my mind.
Trim if P/E re-rates above 49. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 14%. The operating engine is no longer compounding capital efficiently.
Supriya Lifescience Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Supriya Lifescience Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Supriya Lifescience Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Supriya Lifescience Ltd — derived from the live tape, not yesterday's close.
Supriya Lifescience Ltd last traded at ₹977.15 with an intraday range of ₹952.55–₹995 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹977.15| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1082.15 | +105.00 | +10.75% |
| R3 | 1039.70 | +62.55 | +6.40% |
| R2 | 1017.35 | +40.20 | +4.11% |
| R1 | 997.25 | +20.10 | +2.06% |
| PIVOT | 974.90 | -2.25 | -0.23% |
| CURRENT | 977.15 | — | — |
| S1 | 869.90 | -107.25 | -10.98% |
| S2 | 912.35 | -64.80 | -6.63% |
| S3 | 932.45 | -44.70 | -4.57% |
| S4 | 954.80 | -22.35 | -2.29% |
SUPRIYA is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: 952.55 ~ 993.95
Trading Inside opening range
Supriya Lifescience Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Supriya Lifescience Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Supriya Lifescience Ltd stood at 32.1% of traded volume, against a 20-day average of 34.5%.
Supriya Lifescience announcements: results, concalls, ratings, M&A.
Filings Supriya Lifescience sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Supriya Lifescience files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 107 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Supriya Lifescience Limited has informed the Exchange about Transcript
Analysts/Institutional Investor Meet/Con. Call Updates
Supriya Lifescience Limited has informed the Exchange about Link of Recording
Copy of Newspaper Publication
Supriya Lifescience Limited has informed the Exchange about Copy of Newspaper Publication
Press Release
Supriya Lifescience Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Press Release - Audited Financial Results…
Analysts/Institutional Investor Meet/Con. Call Updates
Supriya Lifescience Limited has informed the Exchange about Schedule of meet
Investor decks & rating reports.
Investor Presentation
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation
Investor Presentation
Supriya Lifescience dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Supriya Lifescience has declared, sequenced by announce and record date.
Supriya Lifescience corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Supriya Lifescience Ltd: business, sector, key facts.
What Supriya Lifescience Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Supriya Lifescience Ltd operates in the Healthcare, listed as NSE: SUPRIYA, BSE: 543434.
Supriya Lifescience Limited is a global player in the pharmaceutical industry, specializing in the research, development, manufacturing, and sale of bulk drugs and pharmaceutical chemicals. Their primary focus is on the creation and distribution of Active Pharmaceutical Ingredients (APIs) used in a wide range of therapeutic areas.
The company's API portfolio encompasses various therapeutic segments including anti-histamines, anti-allergics, anti-asthmatics, decongestants, analgesics, antipyretics, anesthetics, anti-hypertensives, anti-malarials, vitamins, and products for treating gout. They also cater to the oncology, veterinary, and general pharmaceutical markets with a diverse range of products.
Beyond their core API business, Supriya Lifescience has expanded into the development and commercialization of specialized healthcare products. This includes GelHeal, a wound care solution, and Quickblue, a kit for the early detection of oral cancer. This diversification demonstrates their commitment to addressing a broader spectrum of healthcare needs.
Looking towards the future, Supriya Lifescience is actively engaged in the research and development of novel drugs across numerous therapeutic areas. Their pipeline includes potential treatments for depression, inflammation, various types of cancers, diabetes, obesity, migraine, and ataxia. They are also exploring opportunities in the development of contrast media, hormones, antibiotics, smoking cessation aids, and veterinary APIs. This aggressive R&D strategy signifies their commitment to innovation and expansion within the pharmaceutical landscape.
Established in 1987 and headquartered in Mumbai, India, Supriya Lifescience has a long history of serving the global pharmaceutical market. Their integrated approach, combining research, manufacturing, and sales, allows them to maintain a strong position in the competitive pharmaceutical industry and continue to explore new avenues for growth and development.
Questions investors ask about Supriya Lifescience Ltd (SUPRIYA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Supriya Lifescience Ltd (SUPRIYA)?
The current share price of Supriya Lifescience Ltd (SUPRIYA) is ₹977.15. Today, the stock has gained by ₹40.15 (4.28%), trading in a range of ₹952.55 to ₹995. The stock opened at ₹960 with a trading volume of 7,09,530 shares.
02Is Supriya Lifescience Ltd stock a good investment for long-term?
Supriya Lifescience Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹7,839.02 crores, P/E ratio of 37.66, ROE of 19.06%, and ROCE of 27.50%. The dividend yield stands at 0.11%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Supriya Lifescience Ltd stock?
The 52-week high price of Supriya Lifescience Ltd (SUPRIYA) is ₹0, while the 52-week low is ₹0. Currently trading at ₹977.15, the stock is Infinity% away from its 52-week low and -Infinity% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Supriya Lifescience Ltd stock at the current price?
Whether to buy Supriya Lifescience Ltd stock at ₹977.15 depends on multiple factors. The stock is currently trading with a P/E ratio of 37.66 and P/B ratio of 6.57. Today's performance shows a gain of 4.28%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Supriya Lifescience Ltd and when is the next dividend?
Supriya Lifescience Ltd offers a dividend yield of 0.11%, which means for every ₹100 invested at the current price of ₹977.15, you can expect to receive approximately ₹0.11 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Supriya Lifescience Ltd?
Supriya Lifescience Ltd's key financial metrics include: P/E Ratio: 37.66, P/B Ratio: 6.57, ROE: 19.06%, ROCE: 27.50%, Dividend Yield: 0.11%, EPS: ₹25.95, Book Value: ₹148.77, and Debt-to-Equity: 0.45. The company's market cap stands at ₹7,839.02 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Supriya Lifescience Ltd stock performing today in the market?
Supriya Lifescience Ltd stock opened at ₹960 and is currently trading at ₹977.15, showing a gain of ₹40.15 (4.28%). The intraday high is ₹995 and low is ₹952.55. The trading volume stands at 7,09,530 shares, indicating moderate market participation today.
08What is the P/E ratio of Supriya Lifescience Ltd and what does it indicate?
Supriya Lifescience Ltd has a Price-to-Earnings (P/E) ratio of 37.66, which means investors are willing to pay ₹37.66 for every ₹1 of earnings. With an EPS of ₹25.95, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Supriya Lifescience Ltd (SUPRIYA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- Top quality scorecard stocksScreener
- EMA Crossover ScreenerScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy